Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability

Design, Synthesis and Pharmacological Evaluation of Naphthofuran Derivatives as Potent SIRT1 Activators

(2021) Jian Gao et al.   Frontiers in Pharmacology

A novel inhibitor L755507 efficiently blocks c-Myc–MAX heterodimerization and induces apoptosis in cancer cells

(2021) Ashutosh Singh et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

MYC protein stability is negatively regulated by BRD4

(2020) Ballachanda N. Devaiah et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of a Novel c-Myc Inhibitor 7594-0037 by Structure-Based Virtual Screening and Investigation of Its Anti-Cancer Effect on Multiple Myeloma

(2020) Ruosi Yao et al.   Drug Design Development and Therapy

DNA double-strand break repair-pathway choice in somatic mammalian cells

(2019) Ralph Scully et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy

(2019) Huiying Han et al.   CANCER CELL

LncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-Myc

(2019) Jiayin Tang et al.   Nature Communications

Novel ubiquitin-independent nucleolar c-Myc degradation pathway mediated by antizyme 2

(2018) Noriyuki Murai et al.   Scientific Reports

Identification of a novel c-Myc inhibitor with antitumor effects on multiple myeloma cells

(2018) Ruosi Yao et al.   BIOSCIENCE REPORTS

Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer

(2018) Lavinia A. Carabet et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

MYC Protein Interactome Profiling Reveals Functionally Distinct Regions that Cooperate to Drive Tumorigenesis

(2018) Manpreet Kalkat et al.   MOLECULAR CELL

LncRNA‐MIF, a c‐Myc‐activated long non‐coding RNA, suppresses glycolysis by promoting Fbxw7‐mediated c‐Myc degradation

(2016) Pengfei Zhang et al.   EMBO REPORTS

Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials

(2016) Brian K. Albrecht et al.   JOURNAL OF MEDICINAL CHEMISTRY

Overexpression of c-myc is associated with adverse clinical features and worse overall survival in multiple myeloma

(2016) Agoston Gyula Szabo et al.   LEUKEMIA & LYMPHOMA

Ubiquitin-Dependent Turnover of MYC Antagonizes MYC/PAF1C Complex Accumulation to Drive Transcriptional Elongation

(2016) Laura A. Jaenicke et al.   MOLECULAR CELL

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

(2016) Sandy Amorim et al.   Lancet Haematology

Oncogene addiction to c-MYC in myeloma cells

(2015) Toril Holien et al.   Oncotarget

Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis

(2014) Arianna Sabò et al.   NATURE

Addiction to c-MYC in multiple myeloma

(2012) T. Holien et al.   BLOOD

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma

(2011) W-J Chng et al.   LEUKEMIA

The impact of MYC expression in lymphoma biology: Beyond Burkitt lymphoma

(2010) Sonali M. Smith et al.   BLOOD CELLS MOLECULES AND DISEASES

Frequent upregulation ofMYCin plasma cell leukemia

(2009) Laura Chiecchio et al.   GENES CHROMOSOMES & CANCER

Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case

(2009) L. Chiecchio et al.   HAEMATOLOGICA

Subcellular Localization of Glycogen Synthase Kinase 3  Controls Embryonic Stem Cell Self-Renewal

(2009) M. Bechard et al.   MOLECULAR AND CELLULAR BIOLOGY

Dysfunctional homologous recombination mediates genomic instability and progression in myeloma

(2008) M. A. Shammas et al.   BLOOD

Pim kinase-dependent inhibition of c-Myc degradation

(2008) Y Zhang et al.   ONCOGENE